戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ts before and after application of a topical decongestant.
2 dications, including specific analgesics and decongestants.
3 , mucolytics, antitussives, antifungals, and decongestants.
4 l infarction (MI) associated with the use of decongestants.
5 unger without previous MI or stroke who used decongestants.
6 ber of associations with oral and intranasal decongestants.
7  95% confidence interval [CI]: -10% to -34%; decongestants: -24%, 95% CI: -13% to -34%; and cough/col
8 use of specific oral and possibly intranasal decongestants and the risk of some infrequent specific b
9 r, were interviewed, including 3.2% who used decongestants during the three weeks prior to the event
10 S may be offered, in addition, an intranasal decongestant for up to 4 weeks.
11                             While intranasal decongestants generally should be limited to short-term
12 l and cardiovascular events in those who use decongestants have triggered alerts related to their use
13 at early pregnancy exposure to specific oral decongestants increases the risks of several birth defec
14 of whom showed improvement and stopped using decongestant nasal spays within 4 weeks.
15                             Long-term use of decongestant nasal spray (alpha adrenergic agonist) caus
16  to answer questions concerning their use of decongestant nasal spray in a questionnaire prior to exa
17 treated with nasal steroid sprays instead of decongestant nasal sprays in our clinic from October, 20
18                                        Nasal decongestant reduces blood flow to the nasal turbinates,
19                                 We also find decongestant regularises nasal airflow and alters the pa
20 eceptor antagonists, short bursts of a nasal decongestant, saline douches and nasal anticholinergics.
21                                         Oral decongestants should be avoided during the first trimest
22                                              Decongestant use in the three weeks preceding the event
23                                   Intranasal decongestants were excluded from the analyses because th